🎉 M&A multiples are live!
Check it out!

Acepodia Valuation Multiples

Discover revenue and EBITDA valuation multiples for Acepodia and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Acepodia Overview

About Acepodia

Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.


Founded

2017

HQ

Taiwan
Employees

n/a

Website

acepodia.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$192M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Acepodia Financials

Acepodia has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Acepodia achieved revenue of $0.5M and an EBITDA of -$23.2M.

Acepodia expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Acepodia valuation multiples based on analyst estimates

Acepodia P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $0.5M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$42.1M -$23.2M XXX XXX XXX
EBITDA Margin NaN% -4607% XXX XXX XXX
Net Profit -$26.6M -$42.9M XXX XXX XXX
Net Margin NaN% -8524% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Acepodia Stock Performance

As of March 17, 2025, Acepodia's stock price is TWD 22 (or $1).

Acepodia has current market cap of TWD 12.3B (or $374M), and EV of TWD 6.3B (or $192M).

See Acepodia trading valuation data

Acepodia Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$192M $374M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Acepodia Valuation Multiples

As of March 17, 2025, Acepodia has market cap of $374M and EV of $192M.

Acepodia's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Acepodia's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Acepodia and 10K+ public comps

Acepodia Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $192M XXX XXX XXX
EV/Revenue 380.9x XXX XXX XXX
EV/EBITDA -8.3x XXX XXX XXX
P/E -15.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -13.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Acepodia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Acepodia Valuation Multiples

Acepodia's NTM/LTM revenue growth is n/a

Acepodia's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Acepodia's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Acepodia's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Acepodia and other 10K+ public comps

Acepodia Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin -4607% XXX XXX XXX XXX
EBITDA Growth -45% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 854% XXX XXX XXX XXX
R&D Expenses to Revenue 1874% XXX XXX XXX XXX
Opex to Revenue 2727% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Acepodia Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Acepodia M&A and Investment Activity

Acepodia acquired  XXX companies to date.

Last acquisition by Acepodia was  XXXXXXXX, XXXXX XXXXX XXXXXX . Acepodia acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Acepodia

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Acepodia

When was Acepodia founded? Acepodia was founded in 2017.
Where is Acepodia headquartered? Acepodia is headquartered in Taiwan.
Is Acepodia publicy listed? Yes, Acepodia is a public company listed on ROCO.
What is the stock symbol of Acepodia? Acepodia trades under 6976 ticker.
When did Acepodia go public? Acepodia went public in 2023.
Who are competitors of Acepodia? Similar companies to Acepodia include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Acepodia? Acepodia's current market cap is $374M
Is Acepodia profitable? Yes, Acepodia is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.